Shire plc reported that SHP-616, a ready-to-use subcutaneous formulation of its C1 esterase inhibitor, Cinryze, significantly reduced hereditary angioedema (HAE) attacks vs. placebo in a phase III study that laid the groundwork for the company to seek regulatory approvals of the candidate.